SCHEMBL2215249

SCHEMBL2215249

CC(C)(N)c1ccc(C(=O)Nc2cccc(Nc3nc(-c4cccc5c4oc4ccccc45)cc4ccnn34)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HPGD P15428 3/20 0.37
HSD17B10 Q99714 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 9/20 0.37
TP53 P04637 4/20 0.37
KCNK9 Q9NPC2 2/20 0.37
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
RXFP1 Q9HBX9 2/20 0.34
KCNK3 O14649 1/20 0.34
GAA P10253 1/20 0.34
BTK Q06187 1/20 0.34
DNMT1 P26358 1/20 0.34
DNMT3L Q9UJW3 1/20 0.34
DNMT3A Q9Y6K1 1/20 0.34
THRB P10828 2/20 0.34
POLB P06746 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2215529 0.95 ALDH1A1 (0.38) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2214311 0.94 KCNK9 (0.44) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2213715 0.89 SMN1; SMN2 (0.38) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2213218 0.88 TRPV1 (0.42) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2214770 0.88 NAMPT (0.34) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2215156 0.87 KDM4E (0.37) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2213042 0.87 LMNA (0.37) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2214233 0.85 DNMT1 (0.42) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2214909 0.85 LOXL2 (0.38) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2216183 0.85 ALDH1A1 (0.42) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1797096-B1 PYRAZOLOPYRIMIDINES AS INHIBITORS OF PROTEIN KINASE B (AKT) BAYER SCHERING PHARMA AG (DE) 2011-07-27 EP disclosed
US-7745446-B2 Pyrazolo[1,5-c]pyrimidines BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-29 US disclosed
US-20070254046-A1 Novel Pyrazolopyrimidines ALTANA PHARMA AG (DE) 2007-11-01 US disclosed
EP-1797096-A2 NOVEL PYRAZOLOPYRIMIDINES Altana Pharma AG (DE) 2007-06-20 EP disclosed
WO-2006027346-A2 NOVEL PYRAZOLOPYRIMIDINES ALTANA PHARMA AG (DE) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254046-A1 Novel Pyrazolopyrimidines MCL1, RARS2, CDK4 SMN1; SMN2 1421/4885KDM4E 3784/4885ALDH1A1 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.